Friday September 21, 2018 13:36

Heathcare Press Release : 13 Sep 2016

Semaglutide Demonstrated Superior HbA1c Reduction vs Placebo as Add-on to Basal Insulin Alone or Heathcare—13 Sep 16

Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic control compared to placebo, as add-on to basal insulin alone or in combination with

Adults with Type 2 Diabetes Treated with Xultophy(R) (IDegLira) were up to 4.5 Times More Likely to Heathcare—13 Sep 16

Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly greater for Xultophy(R) (IDegLira) compared to up-titration with insulin glargine U100 in adults

OGT Expands Cytocell FISH Probe Portfolio for Lung Cancers Heathcare—13 Sep 16

Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched two new CE-IVD labelled fluorescence in situ hybridisation (FISH) probes, further expanding its extensive lung cancer portfolio. The Cytocell Aquarius(R) ROS1 Plus Breakapart and

Merck#s Consumer Health Business Presents New Purpose to Help Prepare Society for 100 Healthy Heathcare—13 Sep 16

- "WE100" movement will promote activities to prepare society for 100 healthy years across generations Merck, a leading science and technology company, revealed the new purpose "Prepare society for a new era of humans living 100 healthy years" for its